Bertram L. Scott
Known title: DirectorCIK: 0001221780
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
BDX Revello Stent Trial Success, Revenue Up 5.4%, Earnings Down 34%. The company announced that its Revello stent achieved strong results in the AGILITY trial for peripheral artery disease patients. Revenue rose 5.4% year‑over‑year, but net earnings fell 34.3%, reflecting higher costs or lower margins. The dividend yield sits at 1.59% and analysts see a target of $194, while the stock trades near the top of its 52‑week range.
Transaction History
| EQH | ▼ Sell | Open Market | 2,780 | $151K | 9/21/2026 | View on chart |
| EQH | ▼ Sell | Open Market | 1,466 | $75K | 8/6/2026 | View on chart |
| EQH | ▼ Sell | Open Market | 2,470 | $101K | 6/4/2026 | View on chart |
| EQH | ▲ Buy | Grant | 4,400 | $185K | 5/20/2026 | View on chart |
| BDX | ▼ Sell | Open Market | 953 | $174K | 2/18/2026 | View on chart |
| BDX | ▲ Buy | Grant | 1,098 | $0 | 1/27/2026 | View on chart |
| BDX | ▼ Sell | Open Market | 217 | $38K | 11/7/2025 | View on chart |
| EQH | ▼ Sell | Open Market | 2,600 | $135K | 8/21/2025 | View on chart |
| EQH | ▲ Buy | Grant | 3,393 | $0 | 5/21/2025 | View on chart |
| BDX | ▼ Sell | Open Market | 700 | $160K | 2/12/2025 | View on chart |
| BDX | ▲ Buy | Grant | 930 | $0 | 1/28/2025 | View on chart |
| EQH | ▲ Buy | Grant | 4,306 | $0 | 5/22/2024 | View on chart |
| EQH | ▼ Sell | Open Market | 7,000 | $247K | 3/18/2024 | View on chart |
| BDX | ▲ Buy | Grant | 900 | $0 | 1/23/2024 | View on chart |
| EQH | ▲ Buy | Grant | 6,473 | $0 | 5/24/2023 | View on chart |
| BDX | ▲ Buy | Grant | 848 | $0 | 1/24/2023 | View on chart |
| EQH | ▼ Sell | Open Market | 7,300 | $218K | 9/8/2022 | View on chart |
| EQH | ▲ Buy | Grant | 5,770 | $0 | 5/19/2022 | View on chart |
| BDX | ▲ Buy | Grant | 820 | $0 | 1/25/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
EQH to Announce Q3 2026 Results; Analysts Examine Fee‑Based Mix and Index Exit
Equitable Holdings has scheduled its third‑quarter 2026 earnings announcement. Recent analysis looks at how a shift toward fee‑based services could affect the company’s earnings mix, and whether the removal of an index and changes in asset‑management turnover might influence its outlook. These factors are being evaluated as the market awaits the upcoming results.
EQH to Announce Q3 2026 Results; Analysts Examine Fee‑Based Mix and Index Exit. Equitable Holdings has scheduled its third‑quarter 2026 earnings announcement. Recent analysis looks at how a shift toward fee‑based services could affect the company’s earnings mix, and whether the removal of an index and changes in asset‑management turnover might influence its outlook. These factors are being evaluated as the market awaits the upcoming results.